of gynecologic cancer patients between February and April 2020.

**Methods** Based on published recommendations, with local Health Direction guidelines we draft the Security Protocol to modulate the access of patients into the DH: to perform visits only of new patients or for clinical urgency and to convert on telemedicine the other contacts; to perform a phone/tele-matic pre-triage the day before the scheduled access and an ‘in site’ pre-triage with measurement of body temperature and administration of a survey for the self-certification of absence risk factors for COVID-19 infection; no caregivers were allowed into DH; surgical masks and gloves were obligatory for anyone.

**Results** We registered 3223 accesses/contacts into our DH for intravenous/oral chemotherapy and visits. The activity was similar to that recorded in 2019 in the same two-month period (3311 accesses). Despite the high patients flow we had only two cases of confirmed COVID-19 infection and no cases among healthcare staff.

**Conclusions** Based on the adopted Security Protocol we have guaranteed continuity of care to all our patients and limited the spread of the COVID-19 infection.

**PROGNOSTIC VALUE AND ASSOCIATION WITH VELIPARIB BENEFIT OF MODELED CA-125 ELIMINATION KINETICS (KELIM) IN PATIENTS WITH NEWLY DIAGNOSED OVARIAN CANCER: ANALYSIS FROM THE VELIA/GOG-3005 STUDY**

1. Yoo 
2. G Fleming 
3. M Bookman 
4. K Moore 
5. K Steffensen 
6. R Coleman

1. ERUCB/CHSL 3738, Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, GINECO, and Centre d’Investigation des Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL), Hospices Civils de Lyon (IC-HCL), France; 2. AbbVie, USA; 3. University of Chicago Medicine, USA; 4. Kaiser Permanente Northern California, USA; 5. Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, USA; 6. Lillebaelt University Hospital of Southern Denmark, and the University of Southern Denmark, Denmark

**Introduction** In VELIA (Phase 3), veliparib with carboplatin/paclitaxel (CP), followed by veliparib maintenance (veliparib-throughout) led to improved progression-free survival (PFS) vs CP alone (control). This exploratory analysis assessed the

**Abstract 36 Figure 1** Progression-free survival in the veliparib throughout arm and the control arm for KELIM subgroups in the PDS population

**Abstract 36 Figure 2** Progression-free survival in the veliparib throughout arm and the control arm for KELIM subgroups in the IDS population

10.1136/ijgc-2020-IGCS.36
prognostic and predictive value of the modeled CA-125 elimination rate constant, KELIM. Methods KELIM was estimated from treatment-related pharmacodynamic modeling of CA-125 values. Median KELIM was used to define favourable ($\geq$median)/unfavourable (<median) KELIM groups. Patients were analyzed by surgery type: primary (PDS) or interval (IDS) debulking surgery.

Results In the IDS population (N=154), patients with favourable KELIM had a higher frequency of complete surgery vs unfavourable KELIM (51.9% vs 32.4%), confirming KELIM as a chemosensitivity marker. In both PDS (N=700) and IDS populations, median PFS was longer with favourable KELIM vs unfavourable KELIM, demonstrating a prognostic value. In the PDS population, median PFS was longer in the veliparib-throughout arm relative to control irrespective of KELIM (29.6 vs. 20.9 and 18.2 vs 15.4 months in favourable and unfavourable KELIM groups, respectively; figure 1). In the IDS population, median PFS was longer with veliparib-throughout vs control for patients with favourable KELIM only (29.3 vs 20.8 months; figure 2).

Conclusion In VELIA, KELIM was prognostic for PFS and IDS outcomes. Current data suggest KELIM may be associated with veliparib benefit. Ongoing analyses will explore how baseline characteristics contribute to KELIM predictive/prognostic value.

IGCS20_1165

QUANTITATIVE EVALUATION OF LYMPH-VASCULAR SPACE INVASION (LVI) IN PATIENTS AFFECTED BY ENDOMETRIAL CANCER: PROGNOSTIC AND CLINICAL IMPLICATIONS

1S Restaino*, 1L Tortorella, 1E Perrone, 1G Monterossi, 1A Gioe, 1L Capasso, 1E La Fera, 2G Dino, 2G Scambia, 6F Fanfani, 6G Zannoni, 4V Chiarchera, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Ginecologia Oncologica, Dipartimento per la Tutela della Salute della Donna e della Vita Nascente, Italy, 1Università Cattolica del Sacro Cuore, Università Gesù, Italy; 2Department of Histopathology, Università Cattolica del Sacro Cuore, Rome, Italy; 6Department of Gynecologic Oncology, University of Palermo, Italy

Objectives Lymph-vascular space invasion (LVI) is associated with an increased risk of recurrence. Usually, the interpretation of LVI is just qualitative, as presence or absence. The aim of this study is to examine the quantitative analysis of LVI.

Methods Retrospective multicentre study. It included 2300 consecutive patients who received a histologically confirmed diagnosis of endometrial cancer between January 2000 and December 2018 at the Gynaecologic Oncology Unit of two tertiary hospitals in Italy.

Results The rate of lymph node metastasis increased from the 5% in patients with no LVI, to 15% in patients with focal LVI and 33% in those with diffuse LVI (p < 0.001). There is a progressive increase of prognostic impact of focal and diffuse LVI on the risk of node metastasis (AOR = 2.12, 95% CI 1.19, 3.79 for focal LVI and AOR = 3.67, 95% CI 2.30, 5.86). Distant recurrences were more frequent in patients with diffuse LVI compared with no LVI (24.9% vs 6.6% respectively, p < 0.001). We found that adjuvant treatments, specifically adjuvant radiations, were associated with improved OS and DFS (median DFS = 19 months vs 97 months respectively for no adjuvant and radiation therapy, p < 0.001) in patients with diffuse LVI.

Conclusion The presence of diffuse LVI is an independent risk factor of both lymph node metastasis and distant recurrence in endometrial cancer patients. It is associated with decreased OS and DFS. Adjuvant radiation improved survival regardless of grading, histotype, and lymph nodal metastasis in women with diffuse LVI.

IGCS20_1184

A TRAINING PROGRAM TO BUILD CAPACITY FOR CERVICAL CANCER PREVENTION IN MOZAMBIQUE

1M Salcedo*, 2M Varon, 1M Varon, 2E Baker, 2E Baker, 2N Osman, 2E David, 2R Rangeiro, 1D Changuge, 5V Andrade, 2OM Oliveira, 2A News, 2I Carrs, 2C Lorenzoni, 2KM Schmeler, 2KM Schmeler. 1Obstetrics and Gynecology Department, Federal University of Health Sciences of Porto Alegre and Mandado Santa Casa de Misericordia de Porto Alegre, Brazil; 2Department of Obstetrics and Gynecology, King Chulalongkorn Memorial Hospital, Thailand; 3Universidade Eduardo Mondlane (UEM), Mozambique; 4Ministerio da Saude de Mozambique (MISAU), Mozambique; 5Hospital Central de Maputo, Mozambique; 6Hospital de Cancer de Barretos, Brazil; 7Diagnostico das Américas-DASA, Brazil; 8Hospital Geral José Macamo, Mozambique, 9Department of Bioengineering, Rice University, USA

Introduction Cervical cancer is the primary cause of cancer among women in Mozambique. There is a shortage of providers trained to deliver cervical cancer screening and manage pre-invasive lesions. We describe a training program to build local capacity to deliver quality cervical cancer prevention services in Mozambique.

Methods The program includes training courses led by faculty from the United States (US) and Brazil, and consists of lectures followed by hands-on training stations to practice colposcopy, cervical biopsy, ablation and loop electrosurgical excision procedure (LEEP) using innovative training models. Participants then perform the procedures in clinic with supportive supervision from the international faculty. The courses are complemented by monthly videoconference telementoring sessions, held in Portuguese using the Project ECHO® (Extension for Community Healthcare Outcomes) model.

Results From 2016 to 2020, 10 courses were held in the cities of Maputo (n=8), Beira (n=1) and Nampula (n=1). There were 347 participants with an average of 34 participants per course. The courses have recently transitioned from only international faculty to include Mozambican gynecologists, including two fellows from the IGCS Global Curriculum program. A total of 15 ECHO sessions were held with ~25 participants/session, 30 patient cases discussed and 14 lectures delivered.

Conclusion This collaboration between Mozambique, Brazil and the US is building local capacity to prevent cervical cancer through training, mentoring and support of local providers. Due to the COVID-19 pandemic, the courses are being transitioned to a virtual format led by the Mozambican doctors with the international faculty joining remotely.